| Literature DB >> 31936727 |
Julen Fernández-Landa1, Diego Fernández-Lázaro2, Julio Calleja-González1, Alberto Caballero-García3, Alfredo Córdova Martínez4, Patxi León-Guereño5, Juan Mielgo-Ayuso4.
Abstract
Creatine monohydrate (CrM) and β-hydroxy β-methylbutyrate (HMB) are common ergogenic aids in the field of sports and are frequently used in an isolated way. However, there are a few studies that have investigated the effect of combining both supplements on different variables related to performance, with controversial results. Therefore, the main purpose of this study was to determine the efficacy and the degree of potentiation of 10 weeks of CrM plus HMB supplementation on sports performance, which was measured by an incremental test to exhaustion in elite male traditional rowers. In this placebo-controlled, double-blind trial, 10-week study, participants (n = 28) were randomized to a placebo group (PLG; n = 7), CrM group (0.04 g/kg/day of CrM; n = 7), HMB group (3 g/day of HMB; n = 7) and CrM-HMB group (0.04 g/kg/day of CrM plus 3 g/day of HMB; n = 7). Before and after 10 weeks of different treatments, an incremental test was performed on a rowing ergometer to calculate the power that each rower obtained at the anaerobic threshold (WAT), and at 4 mmol (W4) and 8 mmol (W8) of blood lactate concentration. There were no significant differences in WAT and W4 among groups or in body composition. However, it was observed that the aerobic power achieved at W8 was significantly higher in the CrM-HMB group than in the PLG, CrM and HMB groups (p < 0.001; η2p = 0.766). Likewise, a synergistic effect of combined supplementation was found for the sum of the two supplements separately at WAT (CrM-HMBG = 403.19% vs. CrMG+HMBG = 337.52%), W4 (CrM-HMBG = 2736.17% vs. CrMG+HMBG = 1705.32%) and W8 (CrM-HMBG = 1293.4% vs. CrMG+HMBG = 877.56%). In summary, CrM plus HMB supplementation over 10 weeks showed a synergistic effect on aerobic power (measured as WAT, W4, and W8) during an incremental test but had no influence muscle mass.Entities:
Keywords: aerobic power; body composition; lactate threshold; muscle mass; muscle recovery; sport nutrition; supplementation
Year: 2020 PMID: 31936727 PMCID: PMC7019716 DOI: 10.3390/nu12010193
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Energy and macronutrient intake in the four study groups during 10 weeks of study.
| PLG | CrMG | HMBG | CrM-HMBG | |
|---|---|---|---|---|
| Energy (kcal) | 3340 ± 350 | 3358 ± 358 | 3290 ± 410 | 3375 ± 395 |
| Energy (kcal/kg) | 44 ± 6 | 45 ± 6 | 45 ± 6 | 45 ± 7 |
| Protein (g) | 143 ± 24 | 145 ± 26 | 141 ± 29 | 143 ± 26 |
| Protein (%) | 17 ± 3 | 18 ± 3 | 18 ± 3 | 17 ± 3 |
| Protein (g/kg) | 2 ± 0 | 2 ± 1 | 2 ± 1 | 2 ± 0 |
| Animal protein (g) | 84 ± 23 | 86 ± 25 | 81 ± 19 | 86 ± 25 |
| Vegetal protein (g) | 60 ± 11 | 58 ± 15 | 62 ± 19 | 59 ± 17 |
| Fat (g) | 101 ± 20 | 103 ± 21 | 99 ± 21 | 101 ± 22 |
| Fat (%) | 27 ± 4 | 28 ± 4 | 27 ± 5 | 28 ± 5 |
| Fat (g/kg) | 2 ± 0 | 2 ± 1 | 2 ± 1 | 2 ± 1 |
| Total carbohydrates (g) | 450 ± 55 | 460 ± 60 | 459 ± 58 | 453 ± 61 |
| Carbohydrates (%) | 54 ± 5 | 55 ± 5 | 55 ± 6 | 54 ± 5 |
| Carbohydrates (g/kg) | 6 ± 1 | 6 ± 1 | 6 ± 1 | 6 ± 1 |
| Fe (mg) | 24 ± 7 | 24 ± 7 | 24 ± 7 | 23 ± 8 |
Data are expressed as mean ± standard deviation. PLG: Placebo group; CrMG: Creatine monohydrate supplemented group; HMBG: HMB supplemented group; CrM-HMBG: Creatine monohydrate plus HMB supplemented group.
Anthropometry and body composition data in the four study groups at the baseline (T1) and after 10 weeks (T2).
| Group | T1 | T2 | P (TxG) | η2 |
|---|---|---|---|---|
| Body mass (Kg) | ||||
| PLG | 81.9 ± 6.3 | 80.0 ± 5.3 * | 0.883 | 0.028 |
| CrMG | 81.2 ± 5.0 | 78.6 ± 5.4 * | ||
| HMBG | 79.9 ± 12.2 | 77.6 ± 11.1 * | ||
| CrM-HMBG | 78.0 ± 4.7 | 75.5 ± 4.5 * | ||
| 6 Skinfolds (mm) | ||||
| PLG | 51.6 ± 18.9 | 48.8 ± 16.3 | 0.790 | 0.050 |
| CrMG | 57.0 ± 6.5 | 54.7 ± 14.1 | ||
| HMBG | 54.2 ± 11.4 | 52.0 ± 13.0 | ||
| CrM-HMBG | 50.4 ± 7.1 | 47.4 ± 4.9 | ||
| Fat mass (kg) | ||||
| PLG | 7.3 ± 2.7 | 6.4 ± 2.3 * | 0.207 | 0.255 |
| CrMG | 6.1 ± 0.7 | 5.8 ± 0.7 * | ||
| HMBG | 6.8 ± 1.3 | 6.3 ± 1.1 * | ||
| CrM-HMBG | 6.4 ± 0.8 | 6.2 ± 0.4 * | ||
| Muscle mass (kg) | ||||
| PLG | 33.3 ± 4.3 | 32.7 ± 4.1 * | 0.442 | 0.160 |
| CrMG | 31.5 ± 1.9 | 31.2 ± 2.3 | ||
| HMBG | 32.8 ± 1.5 | 32.2 ± 1.1 | ||
| CrM-HMBG | 34.6 ± 1.3 | 34.6 ± 1.1 | ||
Data are expressed as mean ± standard deviation. P (TxG): group-by-time interaction (p < 0.05). Two-factor repeated-measures ANOVA. *: Significant difference between study points (T1 vs. T2). p < 0.05. PLG: Placebo group; CrMG: Creatine monohydrate supplemented group; HMBG: HMB supplemented group; CrM-HMBG: Creatine monohydrate plus HMB supplemented group.
Power output at the anaerobic threshold (WAT), 4 (W4) and 8 mmol (W8) in the four study groups at the baseline (T1) and after 10 weeks (T2).
| Group | T1 | T2 | P (TxG) | η2 |
|---|---|---|---|---|
| WAT (W) | ||||
| PLG | 254 ± 34 | 259 ± 20 | 0.228 | 0.168 |
| CrMG | 242 ± 21 | 253 ± 12 | ||
| HMBG | 238 ± 40 | 253 ± 35 * | ||
| CrM-HMBG | 238 ± 22 | 264 ± 19 * | ||
| W4 (W) | ||||
| PLG | 242 ± 16 | 241 ± 31 | 0.196 | 0.181 |
| CrMG | 243 ± 20 | 247 ± 21 | ||
| HMBG | 238 ± 45 | 251 ± 36 | ||
| CrM-HMBG | 236 ± 29 | 262 ± 19 * | ||
| W8 (W) | ||||
| PLG | 317 ± 19 | 314 ± 24 | <0.001 | 0.766 |
| CrMG | 300 ± 20 | 314 ± 21 * | ||
| HMBG | 295 ± 45 | 31 ± 48 * | ||
| CrM-HMBG | 288 ± 21 | 331 ± 35 * | ||
Data are expressed as mean ± standard deviation. P (TxG): group-by-time interaction (p < 0.05. All such occurrences). Two-factor repeated-measures ANOVA. *: Significantly different between study points (T1 vs. T2) p < 0.05. PLG: Placebo group; CrMG: Creatine monohydrate supplemented group; HMBG: HMB supplemented group; CrM-HMBG: Creatine monohydrate plus HMB supplemented group.
Figure 1Percentage changes during study on absolute power output of the anaerobic threshold (WAT), 4 mmol/L (W4) and 8 mmol/L (W8) in the four study groups. Data are expressed as means ± standard error. PLG: Placebo group; CrMG: Creatine monohydrate supplemented group; HMBG: HMB supplemented group; CrM-HMBG: Creatine monohydrate plus HMB supplemented group. Δ: ((T2 − T1)/T1) × 100; differences among groups in each test by ANOVA test (p < 0.05): a: regarding PLG; b: regarding CrMG; c: regarding HMBG.
Determining the effect of the combination of supplements.
| Group | CrMG (A) | HMBG (B) | A + B | CrM-HMBG | CrM-HMBG − (A + B) |
|---|---|---|---|---|---|
|
| 134% | 203% | 338% | 403% | 66% |
|
| 397% | 1309% | 1705% | 2736% | 1031% |
|
| 364% | 514% | 878% | 1293% | 364% |
Data are expressed with respect to change to the placebo group (%) = (Treatment group/placebo (PLG) − 1) × 100 [51]. A + B = Sum of the effects of CrMG (A) and HMBG (B) when participants are supplemented independently.